Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

FDA clearance for Lucid-MS Phase 2 and defined UNBUZZD royalty terms give Quantum BioPharma new clinical and royalty-based value drivers.

Rhea-AI Summary

Quantum BioPharma (QNTM) will present at the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026.

The company will discuss recent milestones, including U.S. FDA approval of its Investigational New Drug application for Lucid-MS, enabling initiation of Phase 2 trials in patients with progressive multiple sclerosis, an area the company describes as a substantial unmet medical need. Lucid-MS is a patented new chemical entity investigational candidate designed to provide neuroprotection by inhibiting demyelination and targeting underlying neurodegeneration.

Quantum also highlights its economics from UNBUZZD™, retaining a 19.48% ownership stake in Unbuzzd Wellness as of June 30, 2026 and a royalty stream of 7% of unbuzzd™ sales until cumulative payments reach $250 million, after which the royalty declines to 3% in perpetuity, while keeping 100% of rights for pharmaceutical and medical formulations.

Positive

• FDA IND clearance for Lucid-MS to begin Phase 2 trials in progressive MS
• 19.48% ownership in Unbuzzd Wellness as of June 30, 2026
• UNBUZZD royalty of 7% of sales until $250 million paid to Quantum
• Perpetual UNBUZZD royalty of 3% of sales after $250 million threshold
• Quantum retains 100% of rights to develop pharma/medical formulations related to UNBUZZD

Negative

• None.

Key Terms

investigational new drug, phase 2, demyelination, new chemical entity

4 terms

investigational new drug regulatory

"the U.S. Food and Drug Administration (FDA) had approved its Investigational New Drug application"

An investigational new drug is a medication that is still being tested in clinical trials to determine if it is safe and effective for treating a specific condition. For investors, it represents a potential breakthrough that could lead to a new treatment and significant financial gains if successful, but also carries risks since it has not yet been approved for widespread use.

phase 2 medical

"to begin Phase 2 trials for the very first time"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

demyelination medical

"designed to provide neuroprotection through the inhibition of demyelination"

Demyelination is the loss or damage of the protective sheath (myelin) that surrounds nerve fibers, similar to how stripped insulation makes electrical wires slower and more error-prone. It matters to investors because diseases or treatments that cause or prevent demyelination can drive clinical trial outcomes, regulatory scrutiny, and long-term costs for healthcare companies; evidence of demyelination can change a drug’s safety profile and therefore a company’s market value.

new chemical entity technical

"Lucid-MS is a patented, new chemical entity investigational drug candidate"

A new chemical entity (NCE) is a drug whose active ingredient has never been previously approved or marketed; it’s a wholly new molecule rather than a new use of an existing compound. For investors, NCEs matter because they offer fresh commercial opportunities, potential patent and regulatory exclusivity, and correspondingly higher upside if successful — but they also carry greater development and regulatory risk, like betting on an untested recipe.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Anthony Durkacz, Co-founder and Executive Co-chairman of the board of Quantum BioPharma, will be presenting on the company’s recent milestones and future growth strategy.

Recently Quantum BioPharma announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational New Drug application for Lucid-MS, to begin Phase 2 trials for the very first time to advance its patented, first-in-class multiple sclerosis (“MS”) program in patients with progressive MS. This is currently an area of substantial unmet medical need within a global MS therapeutics market anticipated to reach approximately US$38.62 billion by 2030 (Grand View Research, 2026).

Lucid-MS is a patented, new chemical entity investigational drug candidate designed to provide neuroprotection through the inhibition of demyelination, a key contributor to disability progression in multiple sclerosis. Unlike most existing therapies that focus primarily on modulating the immune system, Lucid-MS represents a differentiated approach targeting the underlying neurodegeneration—a novel mechanism with the potential to address the root cause of disease advancement in progressive MS.

The ArcStone-Kingswood Growth Summit will be hosting growth issuers and a curated group of investors, family offices, institutional investors, capital market professionals and service providers for a full day of company presentations, networking and 1-on-1 meetings.

Alongside the curated program of 1:1 meetings connecting investors with appropriate projects, the conference program will provide keynote presentation, panel discussions and conversations on the industry developments.

Interested investors who would like to attend the ArcStone-Kingswood Growth Summit can register for a free pass here.

“We’re excited to present Quantum BioPharma to such a large group of potential investors,” said Mr. Durkacz, Co-founder and Executive Co-chairman of the board of Quantum BioPharma.

About ArcStone Securities and Investments Corp.

ArcStone Securities and Investments Corp. is a diversified financial services firm with offices in New York and Toronto. Our firm specializes in providing bespoke solutions to mid-market companies worldwide, with a particular focus on cross-border transactions between Canada and the United States. Our partnership with Kingswood US enhances our ability to offer a full spectrum of financial services to our clients.

About Kingswood US

Kingswood US is a mid-market investment bank with a strong retail equity capital markets franchise and deep rooted investment bank. The firm is dedicated to providing comprehensive financial services, including investment banking, wealth management, and capital raising, to clients across the United States.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. ("Unbuzzd") (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Forward-Looking Information

This press release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable securities law. Any statements that are not statements of historical fact may constitute forward-looking statements. Forward-looking statements are often, but not always, identified by words or phrases such as “believes,” “anticipates,” “expects,” “estimates,” “intends,” “plans,” “forecasts,” “targets,” “hopes,” “may,” “could,” “would,” “will,” “should,” “might” and similar expressions.

Forward-looking statements in this press release include, but are not limited to, statements regarding the Company’s participation in the ArcStone-Kingswood Growth Summit; the anticipated presentation by Anthony Durkacz regarding the Company’s recent milestones and future growth strategy; the Company’s participation in investor meetings and networking activities; the Company’s business plans, objectives and future growth strategy; and the potential opportunities or benefits that may arise from the Company’s participation in the Summit.

Forward-looking statements are based on a number of material factors and assumptions that management believes are reasonable as of the date of this press release, including assumptions regarding the Company’s ability to participate in the Summit as planned; the availability of management and other participants; the Company’s ability to execute its business and development strategies; its ability to obtain sufficient financing on acceptable terms when required; and general economic, market, regulatory and industry conditions. Although the Company considers these assumptions reasonable, they may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, changes to or cancellation of the Summit or the Company’s participation in it; the possibility that investor meetings, presentations or networking activities do not result in anticipated opportunities or benefits; changes in the Company’s business plans or strategy; the Company’s ability to obtain financing and maintain adequate liquidity; risks inherent in the development and commercialization of pharmaceutical and biotechnology products; regulatory and clinical development risks; market and competitive conditions; and the other risk factors identified in the Company’s continuous disclosure filings.

The reader is urged to refer to the additional information relating to Quantum BioPharma, including the risk factors described in its most recent annual report and management’s discussion and analysis, available on SEDAR+ and in the Company’s filings with the U.S. Securities and Exchange Commission through EDGAR, for a more complete discussion of such risk factors and their potential effects.

This list of risk factors should not be construed as exhaustive. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable securities laws. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

Contacts:

Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 304-0323

Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where is Quantum BioPharma presenting at the ArcStone-Kingswood Growth Summit?

Quantum BioPharma will present at the 3rd Annual ArcStone-Kingswood Growth Summit on September 16, 2026, at the Sheraton Center Toronto Hotel in Toronto.

What is Lucid-MS and how is it intended to work?

Lucid-MS is a patented new chemical entity investigational drug candidate intended to provide neuroprotection by inhibiting demyelination, which contributes to disability progression in multiple sclerosis. The company describes it as a differentiated approach targeting underlying neurodegeneration rather than primarily modulating the immune system.

How can investors attend the ArcStone-Kingswood Growth Summit?

Interested investors can register for a free pass to attend the ArcStone-Kingswood Growth Summit. The company directs investors to register via the event’s provided registration link.

What ongoing economic interest does Quantum BioPharma retain in UNBUZZD?

Quantum retains 19.48% ownership in Unbuzzd Wellness as of June 30, 2026, and is entitled to royalties of 7% of unbuzzd™ sales until total royalty payments reach $250 million. After that threshold, the royalty rate decreases to 3% in perpetuity, and Quantum keeps 100% of rights to develop related pharmaceutical and medical products.